A phase 2 trial of ivonescimab, gemcitabine, cisplatin and nab-paclitaxel in gallbladder cancer and other biliary tract cancers, run by First Affiliated Hospital Xi'an Jiaotong University, not yet recruiting.
AK112 Combined With GAP Conversion Therapy for Locally Advanced Gallbladder Cancer is a phase 2 interventional study registered as NCT07767994 by First Affiliated Hospital Xi'an Jiaotong University, with a registry enrolment figure of 22 participants, started 2026-08-28 and due to reach its primary completion in 2028-06-30. Interventions recorded: AK112, Gemcitabine, Cisplatin, Albumin-Bound Paclitaxel /nab-Paclitaxel. Conditions listed: Gallbladder Cancer. No results are recorded here; the registry entry is the source.
Shares Nab-paclitaxel, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
Shares Nab-paclitaxel, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Nab-paclitaxel, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
Shares Nab-paclitaxel, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Gemcitabine, Gallbladder cancer and the tag gallbladder-deep-dive.